```html

Winter Erythema (Cold‑Induced Urticaria)

Overview

Winter erythema, more formally known as cold‑induced urticaria (CIU), is a type of physical urticaria in which exposure to cold temperatures triggers the sudden appearance of itchy, red welts (hives) on the skin. The reaction can occur after brief contact with cold air, water, or objects, and may be triggered more often during the colder months, hence the colloquial term “winter erythema.”

CIU can affect people of any age, but it most commonly begins in adolescents and young adults, with a slight female predominance (approximately 55 % women). The estimated prevalence in the general population ranges from 0.05 % to 0.1 % (1 in 1,000 to 1 in 2,000 people) <sup>[1]</sup>. While most cases are idiopathic, a small proportion are associated with underlying diseases such as infections, hematologic malignancies, or autoimmune disorders.

Symptoms

The hallmark of cold‑induced urticaria is the rapid development of hives after exposure to cold. Symptoms can vary in severity and distribution.

Typical skin findings

• Wheals (hives) – Raised, erythematous, well‑defined plaques that may be pink, red, or flesh‑colored. They usually appear within minutes of cold exposure and resolve within 30–90 minutes.
• Itching (pruritus) – Often intense and may be accompanied by a burning sensation.
• Angio‑edema – Swelling of deeper skin layers, especially around the lips, eyelids, or genitals; less common but important to recognize.
• Cold‑induced flushing – Diffuse redness without raised wheals, seen in some individuals.

Systemic manifestations

• Headache, dizziness, or light‑headedness – May accompany widespread skin involvement.
• Abdominal cramping – Rare, but reported in severe reactions.
• Respiratory symptoms – Throat tightness or wheezing can occur if angio‑edema spreads to the airway.
• Anaphylaxis – A life‑threatening systemic reaction characterized by hypotension, tachycardia, loss of consciousness, or airway obstruction. Occurs in <2–5 % of patients with CIU, often after immersion in cold water or rapid temperature changes <sup>[2]</sup>.

Causes and Risk Factors

Cold‑induced urticaria is classified as a physical urticaria, meaning the trigger is a physical stimulus rather than an allergen. The exact pathophysiology is not fully understood, but several mechanisms have been proposed.

Proposed mechanisms

• IgE‑mediated mast cell degranulation – Cold may cause an abnormal cross‑linking of IgE on mast cells, releasing histamine, leukotrienes, and other mediators that produce hives.
• Cold‑sensitive autoantibodies – In some patients, autoantibodies target receptors on mast cells, leading to activation upon cooling.
• Genetic predisposition – Familial cases have been described, suggesting a hereditary component.

Risk factors

• Age 10–30 years (peak onset).
• Female sex (slightly higher prevalence).
• Family history of physical urticarias.
• Underlying conditions: viral infections (e.g., hepatitis, EBV), autoimmune thyroid disease, lymphoproliferative disorders.
• Medications that lower the threshold for mast cell activation (e.g., non‑steroidal anti‑inflammatory drugs).

Diagnosis

Diagnosis is primarily clinical, based on a clear temporal relationship between cold exposure and urticarial lesions. A structured approach includes:

1. Detailed History

• Onset age, frequency, and seasonality of reactions.
• Specific cold triggers (air, water, refrigerants, cold foods).
• Duration of lesions and any systemic symptoms.
• Medication use, medical history, and family history of urticaria.

2. Physical Examination

• Inspection for wheals, angio‑edema, and any residual hyperpigmentation.
• Vital signs to assess for systemic involvement.

3. Provocative Tests

When the history is equivocal, a controlled challenge test is performed.

• Ice cube test – A 4 °C ice cube is placed in a thin plastic bag, wrapped in a towel, and applied to the forearm for 5 minutes. A positive result is the appearance of a wheal within 10 minutes after removal.
• Cold water immersion test – The patient immerses a hand or foot in 0–4 °C water for 5 minutes; observation for wheal formation follows.

These tests should be performed in a setting equipped for emergency management, as anaphylaxis can occur.

4. Laboratory Studies (optional)

• Complete blood count, ESR, CRP – to rule out systemic inflammation.
• Thyroid panel – because autoimmune thyroid disease co‑exists in ~10 % of cases.
• Serum tryptase – may be elevated after severe reactions.

Treatment Options

Management focuses on symptom control, prevention of triggers, and reducing the risk of severe reactions.

Pharmacologic therapy

• Second‑generation H1 antihistamines (e.g., cetirizine 10 mg daily, loratadine 10 mg daily, fexofenadine 180 mg daily) are first‑line. They are non‑sedating and have a favorable safety profile <sup>[3]</sup>.
• Dose escalation – If standard dosing is insufficient, guidelines allow up‑titration up to 4× the usual dose under physician supervision.
• H2 antagonists (e.g., ranitidine 150 mg BID) can be added for synergistic effect.
• Leukotriene receptor antagonists (e.g., montelukast 10 mg daily) may help in refractory cases.
• Systemic corticosteroids – Short courses (e.g., prednisone 0.5 mg/kg for 5–7 days) for acute severe flares; not recommended for long‑term use due to side effects.
• Biologic therapy – Omalizumab (anti‑IgE) has shown efficacy in antihistamine‑refractory CIU in several small trials (dose 300 mg SC every 4 weeks) <sup>[4]</sup>.

Procedural / Emergency interventions

• Epinephrine auto‑injector – All patients with a history of systemic reactions or who engage in activities with high cold exposure (swimming, winter sports) should carry an auto‑injector (0.3 mg for adults, 0.15 mg for children).
• Cold avoidance devices – Use of insulated gloves, thermal socks, and vapor‑barrier clothing during cold weather.

Lifestyle and trigger avoidance

• Gradual acclimatization is **not** recommended; cold exposure can still provoke reactions.
• Avoid direct contact with ice, cold water, or chilled foods/drinks.
• Use protective barriers (e.g., plastic wrap under gloves) when handling cold objects.
• Keep indoor temperature above 20 °C (68 °F) during winter; use humidifiers to prevent skin drying.
• Stay hydrated and maintain a balanced diet rich in omega‑3 fatty acids, which may modestly reduce urticaria activity.

Living with Winter erythema (cold‑induced urticaria)

While CIU can be distressing, many people lead normal lives with proper planning.

Daily management tips

1. Carry medication – Keep antihistamines and an epinephrine auto‑injector in an easily reachable place (purse, backpack, work desk).
2. Plan outdoor activities – Check weather forecasts; dress in layers; limit exposure time to below 15 minutes in sub‑15 °C environments.
3. Skin care – Apply fragrance‑free moisturizers after bathing to preserve skin barrier; avoid harsh soaps that can exacerbate flushing.
4. Educate friends and family – Teach them how to recognize anaphylaxis and how to administer epinephrine.
5. Medical identification – Wear a medical alert bracelet stating “Cold‑Induced Urticaria – carries epinephrine.”
6. Regular follow‑up – Review medication efficacy every 6–12 months; adjust dosing as needed.

Special situations

• Travel – Pack extra antihistamines and a backup epinephrine injector; request cold‑free meals on planes or trains.
• Sports – For swimmers, use a wetsuit that fully insulates the skin; avoid competition in icy water unless cleared by an allergist.
• Occupational exposure – Workers in refrigeration, food service, or outdoor labor should use insulated gloves and have an emergency action plan at work.

Prevention

Because CIU is triggered by temperature, absolute prevention is impossible, but risk can be minimized.

• Maintain indoor heating during winter; use programmable thermostats to avoid sudden temperature drops.
• Limit exposure to cold foods/drinks – allow them to reach room temperature before consumption.
• Use “warm‑up” techniques before outdoor activities (e.g., brisk walk indoors for 5 minutes).
• Screen new medications for potential mast‑cell activation; avoid NSAIDs if they worsen symptoms.
• Vaccination – Some viral infections precipitate CIU; staying up‑to‑date on vaccinations (influenza, COVID‑19) may reduce trigger events.

Complications

When left untreated or poorly managed, CIU can lead to several issues:

• Anaphylaxis – Rare but potentially fatal; risk rises with large‑area cold immersion.
• Chronic skin changes – Persistent scratching may cause excoriations, hyperpigmentation, or secondary bacterial infection.
• Psychological impact – Anxiety, avoidance of social activities, and reduced quality of life are reported in up to 30 % of patients <sup>[5]</sup>.
• Work or school absenteeism – Frequent flares may interfere with daily responsibilities.

When to Seek Emergency Care

References

1. American Academy of Dermatology. “Physical Urticarias.” 2023. aad.org.
2. Grattan, C. E., & Sussman, G. (2022). Cold‑induced urticaria and anaphylaxis: A review of mechanisms and management. Journal of Allergy and Clinical Immunology, 150(3), 720‑727.
3. Mayo Clinic. “Urticaria (Hives).” Updated 2024. mayo.org.
4. European Academy of Allergy and Clinical Immunology (EAACI). “Omalizumab for chronic urticaria.” 2023 guideline. eaaci.org.
5. World Allergy Organization. “Quality of life in patients with physical urticaria.” 2021. worldallergy.org.

```